Professor, Internal Medicine, Ohio State University College of Medicine
Oncology
Dr. Gregory A. Otterson, MD
|
|
Give Review
Doctor Gregory A. Otterson, MD practices Oncology. He attended Georgetown University School of Medicine. Georgetown University School of Medicine has a rank of 49 in research and a 84 in primary care He received 4 awards: "Regional Top Doctor", "CMS Meaningful Use Stage 1 Certification", "Fellow (FACP)" and "Whos Who in Medicine and Healthcare". Gregory Otterson is also a published doctor. He has 57 publication published. The most recent publication is: NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 4.2016. Gregory Otterson accepts Medicare payments and is listed with Medicare.gov.
Publications
- NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 4.2016.
- Stromal Caveolin-1 Is Associated With Response and Survival in a Phase II Trial of nab-Paclitaxel With Carboplatin for Advanced NSCLC Patients.
- Randomized Phase II Trial of Erlotinib Beyond Progression in Advanced Erlotinib-Responsive Non-Small Cell Lung Cancer.
- CT Gray-Level Texture Analysis as a Quantitative Imaging Biomarker of Epidermal Growth Factor Receptor Mutation Status in Adenocarcinoma of the Lung.
- Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung Cancer (CheckMate 063):...
- Chemotherapy With or Without Maintenance Sunitinib for Untreated Extensive-Stage Small-Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase II Study-...
- Lung Cancer screening, version 1.2015: featured updates to the NCCN guidelines.
- Overexpression of Rad51C splice variants in coloRectal tumors.
- Phase II Study of Nivolumab (anti-PD-1, BMS-936558, ONO-4538) in Patients with Advanced, Refractory Squamous Non-Small Cell Lung Cancer: Metastatic Non-small Cell Lung...
- Y-chromosome status identification suggests a recipient origin of posttransplant non-small cell lung carcinomas: chromogenic in situ hybridization Analysis.
- Erlotinib in African Americans with Advanced Non-Small Cell Lung Cancer: A Prospective Randomized Study with Genetic and Pharmacokinetic Analysis.
- CALGB 30704 (Alliance): A randomized phase II study to assess the efficacy of pemetrexed or sunitinib or pemetrexed plus sunitinib in the second-line treatment of adva...
- NRAS isoforms differentially affect downstream pathways, cell growth, and cell transformation.
- Detection of Extracellular RNAs in Cancer and Viral Infection via Tethered Cationic Lipoplex Nanoparticles Containing Molecular Beacons.
- A phase II study of modulated-capecitabine and docetaxel in chemonaive patients with advanced non-small cell lung Cancer (NSCLC).
- Phase I study of 5-aza-2'-deoxycytidine in combination with valproic acid in non-small-cell lung Cancer.
- Photodynamic Therapy (PDT) May Provide Effective Palliation in the Treatment of Primary Tracheal Carcinoma: A Small Case Series.
- Assessment of FANCD2 nuclear foci formation in paraffin-embedded Tumors: a potential patient-enrichment strategy for treatment with DNA interstrand crosslinking agents.
- Smoking status and survival in the national comprehensive Cancer network non-small cell lung Cancer cohort.
- A phase I study of prolonged infusion of triapine in combination with fixed dose rate gemcitabine in patients with advanced solid Tumors.
- A Dose Escalation and Pharmacodynamic Study of Triapine and Radiation in Patients With Locally Advanced Pancreas Cancer.
- Malignant pleural mesothelioma. Clinical practice guidelines in oncology.
- Vatalanib in malignant mesothelioma: A phase II trial by the Cancer and Leukemia Group B (CALGB 30107).
- A pilot test of a combined tobacco dependence treatment and lung Cancer screening program.
- Randomized Phase II Study of Palifermin for Reducing Dysphagia in Patients Receiving Concurrent Chemoradiotherapy for Locally Advanced Unresectable Non-small Cell Lung...
- The search for an optimal DNA, RNA, and protein detection by in situ hybridization, immunohistochemistry, and solution-based methods.
- MicroRNA-34a is an important component of PRIMA-1-induced apoptotic network in human lung Cancer cells.
- Small cell lung Cancer in never smokers: report of two cases.
- Phase I/II study of inhaled doxorubicin combined with platinum-based therapy for advanced non-small cell lung Cancer.
- Phase I active immunotherapy with combination of two chimeric, human epidermal growth factor receptor 2, B-cell epitopes fused to a promiscuous T-cell epitope in patie...
- MicroRNA 133B targets pro-survival molecules MCL-1 and BCL2L2 in lung Cancer.
- Pulmonary neuroendocrine/carcinoid Tumors: a review article.
- MicroRNAs in the pathogenesis of Lung Cancer.
- The Self-regulation Model of Illness applied to smoking behavior in lung Cancer.
- Expression of a mutant p53 results in an age-related demographic shift in spontaneous Lung tumor formation in transgenic mice.
- Noncytotoxic suramin as a chemosensitizer in patients with advanced non-small-cell lung Cancer: a phase II study.
- HDAC inhibitors act with 5-aza-2'-deoxycytidine to inhibit cell proliferation by suppressing removal of incorporated abases in lung Cancer cells.
- Aberrant DNA methylation of OLIG1, a novel prognostic factor in non-small cell lung Cancer.
- Phase I study of inhaled Doxorubicin for patients with metastatic tumors to the Lungs.
- Differential response between the p53 ubiquitin-protein ligases Pirh2 and MdM2 following DNA damage in human Cancer cells.
- Nontoxic suramin as a chemosensitizer in patients: dosing nomogram development.
- Assessment of tumor necrosis factor alpha blockade as an intervention to improve tolerability of dose-intensive chemotherapy in Cancer patients.
- Acetylation of p53 at lysine 373/382 by the histone deacetylase inhibitor depsipeptide induces expression of p21(Waf1/Cip1).
- Epigenetic modulation of tumor suppressor CCAAT/enhancer binding protein alpha activity in lung Cancer.
- Epigenetic regulation of the tumor suppressor gene TCF21 on 6q23-q24 in lung and head and neck Cancer.
- Phase II evaluation of docetaxel-modulated capecitabine in previously treated patients with non-small cell lung Cancer.
- Expression of Pirh2, a newly identified ubiquitin protein ligase, in lung Cancer.
- A phase I/II study of LY900003, an antisense inhibitor of protein kinase C-alpha, in combination with cisplatin and gemcitabine in patients with advanced non-small cel...
- 5-aza-2'-deoxycytidine activates the p53/p21Waf1/Cip1 pathway to inhibit cell proliferation.
- Phase I study of low-dose suramin as a chemosensitizer in patients with advanced non-small cell lung Cancer.
- P21 response to DNA damage induced by genistein and etoposide in human lung Cancer cells.
- Methylation of adjacent CpG sites affects Sp1/Sp3 binding and activity in the p21(Cip1) promoter.
- Pharmacobiologically based scheduling of capecitabine and docetaxel results in antitumor activity in resistant human malignancies.
- Fanconi anemia repair pathway dysfunction, a potential therapeutic target in lung Cancer.
- Clinical and Metabolic Parameters in Non-Small Cell Lung Carcinoma and Colorectal Cancer Patients with and without KRAS Mutations.
- Increased NQO1 but Not c-MET and Survivin Expression in Non-Small Cell Lung Carcinoma with KRAS Mutations.
Schools
Georgetown University School Of Medicine
Rush Presby St Lukes
National Canc Institute
Procedures Preformed
- Thoracentesis
Conditions Treated
- Acute Leukemia
- Adrenal Gland Cancer
- Anal and Rectal Cancer
- Anemia
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- Regional Top Doctor
- CMS Meaningful Use Stage 1 Certification
- Fellow (FACP)
- Whos Who in Medicine and Healthcare
Education
-
National Institutes of Health Clinical Center -
Rush University Medical Center -
Georgetown University School of Medicine
Hospital
-
Ohio State University Wexner Medical Center
Drug Facts
| NPI NUMBER | 1215945548 | |
| NPPES Provider LastName | OTTERSON | |
| NPPES Provider FirstName | GREGORY | |
| NPPES Provider ZIPCode | 432101280 | |
| NPPES Provider State | OH | |
| Specialty Description | Medical Oncology | |
| Total Claim Count | 94.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1215945548 |
| Last Name Of The Provider | OTTERSON |
| First Name Of The Provider | GREGORY |
| View All |
Similar Doctors
|
|
Dr. Samantha M. Jaglowski, MD
 This Doctor is OpenDoctor Recommended.
|